Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBIT (2016 - 2025)

Historic EBIT for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $40.8 million.

  • Arrowhead Pharmaceuticals' EBIT rose 12528.25% to $40.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $300.6 million, marking a year-over-year increase of 14801.8%. This contributed to the annual value of $98.3 million for FY2025, which is 11636.15% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' EBIT is $40.8 million, which was up 12528.25% from $44.1 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' EBIT's 5-year high stood at $381.2 million during Q1 2025, with a 5-year trough of -$176.1 million in Q2 2024.
  • In the last 5 years, Arrowhead Pharmaceuticals' EBIT had a median value of -$68.9 million in 2021 and averaged -$48.5 million.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 36199.73% in 2024, then surged by 40208.33% in 2025.
  • Arrowhead Pharmaceuticals' EBIT (Quarter) stood at -$63.3 million in 2021, then skyrocketed by 33.46% to -$42.1 million in 2022, then plummeted by 224.07% to -$136.5 million in 2023, then fell by 18.21% to -$161.4 million in 2024, then soared by 125.28% to $40.8 million in 2025.
  • Its last three reported values are $40.8 million in Q4 2025, $44.1 million for Q3 2025, and -$165.5 million during Q2 2025.